Dachaigh › Aillse Sgamhain Neo-chealla-beag › Montana › Billings
Sgrùdaidhean clionaigeach Aillse Sgamhain Neo-chealla-beag ann an Billings, MT
Tha 17 sgrùdaidhean airson Aillse Sgamhain Neo-chealla-beag a’ lorg phàirtichean aig làraichean ann agus timcheall air Billings (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
A’ fastadhÌre 3
- St. Vincent Frontier Cancer Center-Research ( Site 0105), Billings
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
A’ fastadhÌre 3
- Billings Clinic Cancer Center, Billings
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
A’ fastadhÌre 3
- Billings Clinic Cancer Center, Billings
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
A’ fastadhÌre 3
- Billings Clinic ( Site 3255), Billings
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
A’ fastadhÌre 3
- Billings Clinic Cancer Center, Billings
- Saint Vincent Frontier Cancer Center, Billings
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
A’ fastadhÌre 3
- St. Vincent Frontier Cancer Center, Billings
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
A’ fastadhÌre 3
- Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana, Billings
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
A’ fastadhÌre 3
- SCL Health - Montana, Billings
- SCL Health - Montana, Billings
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
A’ fastadhÌre 2
- Billings Clinic Cancer Center, Billings
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
A’ fastadhÌre 2
- St. Vincent Frontier Cancer Center, Billings
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
A’ fastadhÌre 1/2
- Intermountain Health - St. Vincent Frontier Cancer Center, Billings
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
A’ fastadhÌre 2
- Billings Clinic Cancer Center, Billings
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
A’ fastadhÌre 2
- Billings Clinic Cancer Center, Billings
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
A’ fastadhÌre 2/3
- Billings Clinic Cancer Center, Billings
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
A’ fastadhÌre 2
- Billings Clinic Cancer Center, Billings
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
A’ fastadhSgrùdadh amharc
- Billings Clinic Cancer Center, Billings
- Montana Cancer Consortium NCORP, Billings
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
A’ fastadhSgrùdadh amharc
- Massive Bio SYNERGY-AI site, Billings
Sgrùdaidhean Aillse Sgamhain Neo-chealla-beag ann am bailtean eile
- Houston, TX145 sgrùdaidhean
- New York City, NY121 sgrùdaidhean
- Arlington, VA104 sgrùdaidhean
- Nashville, TN97 sgrùdaidhean
- Boston, MA90 sgrùdaidhean
- Los Angeles, CA87 sgrùdaidhean
- St. Louis, MO73 sgrùdaidhean
- Chicago, IL61 sgrùdaidhean
- Baltimore, MD60 sgrùdaidhean
- San Antonio, TX59 sgrùdaidhean
- Columbus, OH57 sgrùdaidhean
- Washington, DC55 sgrùdaidhean
Sgrùdaidhean eile ann an Billings
- Aillse Prostata15 sgrùdaidhean
- Ailseachadh nan Sgamhan13 sgrùdaidhean
- Aillse a' bhroilleach10 sgrùdaidhean
- Cancer Ovarian9 sgrùdaidhean
- Melanoma7 sgrùdaidhean
- Leukemia Lymphocytic Cronach7 sgrùdaidhean
- Leukemia myeloid geur7 sgrùdaidhean
- Aillse sa bhlaire6 sgrùdaidhean
- Aillse colon6 sgrùdaidhean
- Aillse colorectal6 sgrùdaidhean
- Aillse an Rectum5 sgrùdaidhean
- Carcinoma Cealla Sgamach a' Chinn agus a' Mhuineil4 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.